Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma.

MLA

McElree, Ian M., et al. “Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma.” Cancers, vol. 16, no. 24, Dec. 2024, p. 4126. EBSCOhost, https://doi.org/10.3390/cancers16244126.

APA

McElree, I. M., Packiam, V. T., Steinberg, R. L., Hougen, H. Y., Abou Chakra, M., Mott, S. L., & O’Donnell, M. A. (2024). Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma. Cancers, 16(24), 4126. https://doi.org/10.3390/cancers16244126

Chicago

McElree, Ian M., Vignesh T. Packiam, Ryan L. Steinberg, Helen Y. Hougen, Mohamad Abou Chakra, Sarah L. Mott, and Michael A. O’Donnell. 2024. “Sequential Endoluminal Doxorubicin and Gemcitabine Alternating Weekly with Sequential Mitomycin and Docetaxel for Recurrent Non-Muscle Invasive Urothelial Carcinoma.” Cancers 16 (24): 4126. doi:10.3390/cancers16244126.